Reducing patient eligibility criteria in cancer clinical trials
- PMID: 8648395
- DOI: 10.1200/JCO.1996.14.4.1364
Reducing patient eligibility criteria in cancer clinical trials
Abstract
Purpose: To discuss patient eligibility criteria in phase III cancer clinical trials in the larger setting of the complexity of these trials, to review the various reasons for imposing restrictive eligibility requirements, to discuss the problems caused by these requirements, to argue that these requirements should be greatly relaxed in most cancer clinical trials, to provide some guiding principles and practical suggestions to facilitate such a relaxation, and to give an example of how eligibility requirements were reduced in a recent clinical trial in acute lymphocytic leukemia.
Methods: Implicit and explicit reasons for including eligibility criteria in clinical trials are reviewed. Safety concerns and sample size issues receive special attention. The types of problems restrictive eligibility criteria cause with respect to scientific interpretation, medical applicability, complexity, costs, and patient accrual are described.
Results: A list of three items that each eligibility criterion should meet in order to be included is proposed and applied to a recent trial in acute lymphocytic leukemia.
Conclusion: Phase III clinical trials in cancer should have much broader eligibility criteria than the traditionally restrictive criteria commonly used. Adoption of less restrictive eligibility criteria for most studies would allow broader generalizations, better mimic medical practice, reduce complexity and costs, and permit more rapid accrual without compromising patient safety or requiring major increases in sample size.
Similar articles
-
Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.Clin Trials. 2012 Oct;9(5):652-9. doi: 10.1177/1740774512456453. Clin Trials. 2012. PMID: 23060323
-
Comparison of Eligibility Criteria Between Protocols, Registries, and Publications of Cancer Clinical Trials.J Natl Cancer Inst. 2016 May 25;108(11). doi: 10.1093/jnci/djw129. Print 2016 Nov. J Natl Cancer Inst. 2016. PMID: 27226519
-
Eligibility criteria for phase I clinical trials: tight vs loose?Cancer Chemother Pharmacol. 2019 May;83(5):999-1002. doi: 10.1007/s00280-019-03801-w. Epub 2019 Feb 27. Cancer Chemother Pharmacol. 2019. PMID: 30809701 Review.
-
Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001.J Clin Oncol. 2005 Apr 1;23(10):2201-7. doi: 10.1200/JCO.2005.01.222. J Clin Oncol. 2005. PMID: 15800312 Clinical Trial.
-
Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual.Clin Cancer Res. 2016 Nov 15;22(22):5408-5416. doi: 10.1158/1078-0432.CCR-16-0338. Epub 2016 Jul 11. Clin Cancer Res. 2016. PMID: 27401246 Free PMC article. Review.
Cited by
-
Feasibility of feature-based indexing, clustering, and search of clinical trials. A case study of breast cancer trials from ClinicalTrials.gov.Methods Inf Med. 2013;52(5):382-94. doi: 10.3414/ME12-01-0092. Epub 2013 May 13. Methods Inf Med. 2013. PMID: 23666475 Free PMC article.
-
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.EMBO Mol Med. 2013 Jul;5(7):1051-66. doi: 10.1002/emmm.201201823. Epub 2013 May 13. EMBO Mol Med. 2013. PMID: 23666744 Free PMC article.
-
Comparison of survival outcomes among cancer patients treated in and out of clinical trials.J Natl Cancer Inst. 2014 Mar;106(3):dju002. doi: 10.1093/jnci/dju002. Epub 2014 Mar 13. J Natl Cancer Inst. 2014. PMID: 24627276 Free PMC article.
-
Stratified randomization for platform trials with differing experimental arm eligibility.Clin Trials. 2021 Oct;18(5):562-569. doi: 10.1177/17407745211028872. Epub 2021 Aug 21. Clin Trials. 2021. PMID: 34420417 Free PMC article.
-
Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study.J Oncol. 2020 Jun 20;2020:6423936. doi: 10.1155/2020/6423936. eCollection 2020. J Oncol. 2020. PMID: 32655639 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources